Aviragen Therapeutics (AVIR) Misses Q4 EPS by 13c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.57), $0.13 worse than the analyst estimate of ($0.44).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Electra Therapeutics files for proposed IPO
• AiRWA receives Nasdaq deficiency notice over late 10-K filing
• BofA Securities Starts SBI Funds Management (SBIFUNDS:IN) at Buy